



**Cover Image**

Schematic Venn diagram of risk factors, clinical features, and pathophysiologic characteristics that are more prevalent as part of tics in Tourette syndrome (nonoverlapping section of left circle), more prevalent as part of functional tic-like movements (nonoverlapping section of right circle), and those that often overlap with features common to both. Stylized by Kaitlyn Aman Ramm, *Neurology* Editorial Assistant.

See page 750

**In Focus**

727 **Spotlight on the October 22 issue**

728 **This Week's *Neurology*® Podcast**

**Special Editorial**

729 **End of life: Expert care and support, not physician-hastened death**

J.C. Masdeu, A.J. Aksamit, A.C. Carver, K.M. Foley, J.S. Kass, R.A. Martin, E.A. McCusker, M.P. McQuillen, R. Mehanna, R. Payne, S.J. Victor, and S. Warach

Open Access Article

**Editorials**

735 **Natalizumab wearing-off symptoms: Patients with MS on extended interval dosing may not “mind the gap”**

E.M. Mowry and D. Bourdette

737 **Screening with a high-precision blood-based assay for Alzheimer disease**

B.B. Bendlin and H. Zetterberg

**Articles: Short Format**

Full articles at [Neurology.org/N](http://Neurology.org/N)

739 **The natalizumab wearing-off effect: End of natalizumab cycle, recurrence of MS symptoms**

Z.L.E. van Kempen, D. Doesburg, I. Dekker, B.I. Lissenberg-Witte, A. de Vries, I.A. Claessen, A. Brinke, T. Rispens, and J. Killestein

➔ Editorial, p. 735

740 **Characteristics of acquired transthyretin amyloidosis: A case series and review of the literature**

Y. Misumi, M. Ueda, T. Masuda, Y. Tsuda, T. Nomura, M. Okada, Y. Inoue, M. Tasaki, K. Obayashi, T. Yamashita, and Y. Ando

741 **Relationships between DMD mutations and neurodevelopment in dystrophinopathy**

M. Thangarajh, J. Hendriksen, M.P. McDermott, W. Martens, K.A. Hart, and R.C. Griggs, for The Muscle Study Group and TREAT-NMD

742 **Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers**

A.J. Cammack, N. Atassi, T. Hyman, L.H. van den Berg, M. Harms, R.H. Baloh, R.H. Brown, M.A. van Es, J.H. Veldink, B.S. de Vries, J.D. Rothstein, C. Drain, J. Jockel-Balsarotti, A. Malcolm, S. Boodram, A. Salter, N. Wightman, H. Yu, A.V. Sherman, T.J. Esparza, D. McKenna-Yasek, M.A. Owegi, and C. Douthwright, Alzheimer's Disease Neuroimaging Initiative, A. McCampbell, T. Ferguson, C. Cruchaga, M. Cudkowicz, and T.M. Miller

743 **Outcome of endovascular therapy in stroke with large vessel occlusion and mild symptoms**

C. Manno, G. Disanto, G. Bianco, S. Nannoni, M. Heldner, S. Jung, M. Arnold, J. Kaesmacher, M. Müller, S. Thilemann, H. Gensicke, E. Carrera, U. Fischer, T. Kahles, A. Luft, K. Nedeltchev, C. Staedler, A. Cianfoni, G. Kägi, L.H. Bonati, P. Michel, and C.W. Cereda

➔ Class of Evidence

744 **The role of small diffusion-weighted imaging lesions in cerebral small vessel disease**

K. Wiegertjes, A. ter Telgte, P.B. Oliveira, E.M.C. van Leijssen, M.I. Bergkamp, I.W.M. van Uden, M. Ghafoorian, H.M. van der Holst, D.G. Norris, B. Platel, C.J.M. Klijn, A.M. Tuladhar, and F.-E. de Leeuw

➔ CME Course

745 **Applying the ATN scheme in a memory clinic population: The ABIDE project**

D. Altomare, A. de Wilde, R. Ossenkoppele, W. Pelkmans, F. Bouwman, C. Groot, I. van Maurik, M. Zwan, M. Yaqub, F. Barkhof, B.N. van Berckel, C.E. Teunissen, G.B. Frisoni, P. Scheltens, and W.M. van der Flier

➔ CME Course

746 **High-precision plasma  $\beta$ -amyloid 42/40 predicts current and future brain amyloidosis**

S.E. Schindler, J.G. Bollinger, V. Ovod, K.G. Mawuenyega, Y. Li, B.A. Gordon, D.M. Holtzman, J.C. Morris, T.L.S. Benzinger, C. Xiong, A.M. Fagan, and R.J. Bateman

➔ Editorial, p. 737 ➔ Podcast ➔ Class of Evidence

**What's Happening**

747 **What's happening in *Neurology*®**

748 **What's happening in *Neurology*® Genetics**

749 **What's happening in Without Borders**

**Views & Reviews**

750 **Tics and functional tic-like movements: Can we tell them apart?**

C. Ganos, D. Martino, A.J. Espay, A.E. Lang, K.P. Bhatia, and M.J. Edwards

**➔ Ahead of Print Articles and Editorials**

[NPub.org/aheadofprint](http://NPub.org/aheadofprint)

*Continued*

**Resident & Fellow Section**759 **Clinical Reasoning: A case of acute encephalopathy and rigidity in a 30-year-old man**

B. Hurtubise and A. MacLellan

e1660 **Teaching NeuroImages: Electroretinographic artifacts in EEG**

P.S. Ng, Y.-I. Tan, A. Sivalingam, and S. Neo

e1662 **Teaching NeuroImages: Diffuse cerebrovascular susceptibility artifact following ferumoxytol infusion**

P. Gastrell, J. Carrera, P. Batchala, and A. Southerland

**Disputes & Debates: Editors' Choice**764 **Editors' note: Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology**

A. Ganesh and S. Galetta

764 **Reader response: Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology**

K. R. Tran

765 **Author response: Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology**

A. D. Rae-Grant

766 **Editors' note: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy**

A. Ganesh and S. Galetta

766 **Reader response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy**

J. Jankovic

767 **Author response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy**

P. Albrecht, A. Jansen, J.-I. Lee, M. Ringelstein, O. Aktas, H.-P. Hartung, H. Bigalke, and H. Hefter

768 **Reader response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy**

E. Mulroy, B. Balint, and A. Batla

768 **Author response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy**

P. Albrecht, A. Jansen, J.-I. Lee, M. Ringelstein, O. Aktas, H.-P. Hartung, H. Bigalke, H.-P. Hartung, and H. Hefter

**Correction**769 **Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology****Department**In the Next Issue of *Neurology*<sup>®</sup>

---

**Share Your Artistic Expressions in *Neurology* 'Visions'**

AAN members are urged to submit medically or scientifically related artistic images, such as photographs, photomicrographs, and paintings, to the "Visions" section of *Neurology*<sup>®</sup>. These images are creative in nature, rather than the medically instructive images published in the NeuroImages section. The image or series of up to six images may be black and white or color and must fit into one published journal page. Accompanying description should be 100 words or less; the title should be a maximum of 96 characters including spaces and punctuation.

Please access the Author Center at [NPub.org/authors](http://NPub.org/authors) for full submission information.

---